Drug Type Biosimilar, Monoclonal antibody |
Synonyms Bevacizumab Biosimilar (Shanghai Huaaotai Biopharmaceutical Co., Ltd.), 贝伐珠单抗生物类似药(Shanghai Huaaotai Biopharmaceutical Co., Ltd.), 重组人源化抗血管内皮生长因子 (VEGF)单抗 (上海华奥泰生物) + [2] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 19 Aug 2022 | |
Metastatic Colorectal Carcinoma | Phase 3 | CN | 19 Aug 2022 | |
Non-squamous non-small cell lung cancer | Phase 3 | CN | 16 Mar 2021 | |
Non-Small Cell Lung Cancer | Preclinical | CN | 24 Jun 2019 | |
Glioma | Discovery | CN | 07 Mar 2013 | |
Ovarian Cancer | Discovery | CN | 07 Mar 2013 | |
Renal Cell Carcinoma | Discovery | CN | 07 Mar 2013 |